Clinical trials
Phase 2 Study clinical trials
Below are recruiting phase 2 study clinical trials, each written for real people, not researchers. We’re tracking 1,323 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06731218RecruitingPhase 1
A study on RGB-5088 for type 1 diabetes
This trial tests a new treatment called RGB-5088 in people with type 1 diabetes. It aims to see if the treatment is safe and if it helps control blood sugar.
Tianjin, Tianjin MunicipalityAges 18–60 - NCT06723080RecruitingPhase 3
Oral VC005 for moderate to severe eczema
This study tests an investigational oral tablet (VC005) for adults with moderate to severe atopic dermatitis (eczema). It is for people whose eczema has not been controlled well enough with topical treatments.
Nanjing, JiangsuAges 18–75 - NCT06700070RecruitingEarly Phase 1
Testing a microdose drug in solid tumors before surgery
This study tests a tiny amount of an experimental drug (PBA-0111) injected directly into tumors that will be surgically removed later. The goal is to see how the drug affects the tumor tissue, which may help guide future treatments for solid tumors like head and neck cancer, certain sarcomas, or triple-negative breast cancer.
Shreveport, LouisianaAges 18 years+ - NCT06692712RecruitingPhase 3
Gene therapy study for children with SPG50
This study tests a gene therapy called IT MELPIDA for children with SPG50, a genetic condition that affects movement and development. The treatment is given through a lumbar puncture (spinal tap) and aims to slow or stop the loss of motor skills.
Dallas, TexasAges 4 months–6 years - NCT06255392RecruitingPhase 3
Fluzoparib with apatinib vs chemo for advanced breast cancer
This trial tests a combination of two oral targeted drugs (fluzoparib and apatinib) against standard chemotherapy for women with advanced, HRD-positive, HER2-negative breast cancer. It may be an option if you have already received some treatments but not too many.
Guangzhou, GuangdongAges 18–70 - NCT06651593RecruitingPhase 2
BND-22 and cemiplimab for advanced solid tumors
This trial tests a combination of two new drugs, BND-22 and cemiplimab, for people with certain advanced solid tumors like lung, colorectal, or ovarian cancer. It aims to see if this treatment helps control the cancer and looks at specific markers in your blood and tissue.
Houston, TexasAges 18 years+ - NCT06639256RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial is testing a new drug called HY07121 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
JinanAges 18–80 - NCT06552234RecruitingPhase 2
Study of repotrectinib for older or frail patients with ROS1-positive lung cancer
This trial tests an oral targeted therapy called repotrectinib in people with advanced non-small cell lung cancer (NSCLC) that has a change in the ROS1 gene. It is designed for patients who are either 70 or older, or have a lower performance status (ECOG 2 or higher), meaning they may be more frail or have more symptoms. The goal is to see if repotrectinib can help shrink or control the cancer.
Aix-en-Provence, Bouches Du RhôneAges 18 years+ - NCT06532006RecruitingPhase 3
HLX22 plus trastuzumab and chemo for HER2+ stomach cancer
This trial tests adding a new drug, HLX22, to the standard combination of trastuzumab and chemotherapy for people with HER2-positive stomach or gastroesophageal junction cancer that hasn't been treated yet. The goal is to see if this three-drug mix works better than the usual two-drug approach.
Anaheim, CaliforniaAges 18 years+ - NCT06474455RecruitingPhase 1/Phase 2
Study of SHR-9839 with other treatments for advanced solid tumors
This trial tests a new drug called SHR-9839 combined with other cancer treatments for people with advanced solid tumors, including a certain type of lung cancer. The goal is to see if the combination is safe and effective against the cancer.
Zhengzhou, HenanAges 18–75 - NCT06423170RecruitingPhase 2
Camrelizumab plus chemo for unresectable gallbladder cancer
This trial tests a combination of the immunotherapy drug camrelizumab with two chemotherapy drugs (gemcitabine and oxaliplatin, known as GEMOX) for people with gallbladder cancer that cannot be surgically removed. It aims to see if this treatment can help shrink the tumor and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06383871RecruitingPhase 1
A study of the new drug HRS-7058 for advanced solid tumors
This is a phase 1 study testing a new oral drug called HRS-7058 for people with advanced solid tumors that have not responded to other treatments. The main goal is to find a safe dose and see how well the drug works.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06238401RecruitingPhase 1
Testing ACR246 for advanced solid tumors
This trial tests a new drug called ACR246 for people with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see if the drug can shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT06144671RecruitingPhase 1/Phase 2
Custom immune cell therapy for advanced solid tumors
This study tests a new treatment that uses your own immune cells, called TIL, to fight advanced solid tumors. It may be given alone or with another drug that helps the immune system attack cancer. The goal is to see if this treatment is safe and effective for people who have already tried other treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06139575RecruitingPhase 1/Phase 2
A study of a new drug for advanced prostate cancer
This trial tests a radioactive drug called Lu 177 JH020002 for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly, possibly slowing the disease.
Hefei, AnhuiAges 18 years+ - NCT06080503Recruiting
Comparing shorter vs. standard radiation for early vocal cord cancer
This study tests if a shorter course of radiation (hypofractionated) works as well as the standard longer course for people with early-stage cancer of the vocal cords. The goal is to find a treatment that is more convenient and has similar results.
Dallas, TexasAges 18 years+ - NCT05751018RecruitingPhase 2
Pyrotinib for first treatment of HER2-mutated lung cancer
This Phase 2 trial studies pyrotinib as a first (initial) anti-cancer treatment for advanced lung cancer that has specific HER2 changes. It aims to shrink tumors and control the cancer, especially in people whose test results show HER2 insertion mutation, point mutation, or amplification.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05668403RecruitingPhase 1
Subcutaneous anti-CD20 antibody for primary membranous nephropathy
This Phase 1 study tests a skin-under-the-bone (subcutaneous) antibody medicine that targets CD20 on certain immune cells. It aims to see safety and how the drug may work in people with primary membranous nephropathy, a kidney disease that can cause high urine protein.
Zhengzhou, He'nanAges 18–75 - NCT05641688RecruitingPhase 3
PET brain scan study for people with terminal illness
This Phase 3 study tests an amyloid/tau PET brain imaging agent (called [18F]PI-2620). It aims to see how well the scan helps with brain pathology findings in people who are expected to have a life expectancy of 1 year or less.
Phoenix, ArizonaAges 50 years+ - NCT05631964RecruitingPhase 1
Early trial of BL-M07D1 for advanced HER2-positive digestive tumors
This early-phase trial tests BL-M07D1 in people with advanced digestive tract (and other solid) cancers that can’t be removed with surgery and have already tried or can’t use standard treatment. It’s studying whether the drug works and how safe it is, and whether HER2 tumor results are linked to benefit.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05457829RecruitingPhase 2
Testing two chemotherapy combinations for relapsed pediatric rhabdomyosarcoma
This trial compares two treatment combinations—liposomal doxorubicin plus irinotecan versus a different chemotherapy plan—in children and teens whose rhabdomyosarcoma came back or did not respond. It aims to see which option works better and is safer for children who have had prior cancer treatment.
GuangzhouAges 6 months–18 years - NCT05170958RecruitingPhase 1/Phase 2
Study of LBL-024 for advanced cancers
This trial tests LBL-024 in people with advanced cancer to see how it works and how safe it is. You may consider it if you are well enough for study visits and have time to complete at least about 12 weeks of follow-up.
Hefei, AnhuiAges 18–80 - NCT05039632RecruitingPhase 1/Phase 2
NBTXR3 plus radiation with anti-PD-1 for advanced lung or liver cancers
This study tests whether adding NBTXR3 (given into a tumor) and targeted radiation to anti–PD-1/PD-L1 immunotherapy can improve cancer control in advanced cancers that have spread to the lung and/or liver. Participants may be assigned to different radiation approaches to try to trigger tumor shrinkage in both treated and nearby or distant tumor areas.
Houston, TexasAges 18 years+ - NCT04566380RecruitingPhase 2
Study for people already taking ONO-4538
This trial is for people who are already being treated with ONO-4538 (either alone or with other treatments) and can continue into an “extension/rollover” study. It checks how well ONO-4538 continues to work and is used safely over more time.
Chiba, ChibaAges 16 years+
Hear when a new Phase 2 Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for phase 2 study?
- Yes. Clin2 currently lists 1,323 recruiting phase 2 study studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a phase 2 study trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a phase 2 study trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.